Please ensure Javascript is enabled for purposes of website accessibility

Trump Scales Up Coronavirus Response with Quarantines and Travel Restrictions

By Mark Prvulovic - Jan 31, 2020 at 7:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The president declared the spreading coronavirus to be a public health emergency.

After monitoring the situation, the Trump administration officially declared the coronavirus a public health emergency and will be implementing travel restrictions and mandatory quarantines.

Alex Azar, Health and Human Services Secretary, said that the President signed an order to deny the entry of foreign nationals who have been in China in the past two weeks. U.S. citizens who are returning from the Hubei province of China, where the outbreak is at its worst, will be subject to a 14-day mandatory quarantine period to guarantee they aren't infected with the coronavirus.

A picture of a quarantine sign on a wall.

Image source: Getty Images.

While the Center for Disease Control and Prevention has reiterated that the country is still at a "low" risk level at this time, coronavirus cases are continuing to spread in countries outside of China. Additionally, Homeland Security deputy secretary Ken Cuccinelli has said that incoming flights from China will be restricted to just seven airports as of Sunday. These include New York's JFK, San Francisco, Los Angeles International Airport, Seattle, Atlanta, Honolulu, and Chicago's O'Hare airport.

Coronavirus statistics

At the time of writing, there have been 9,925 confirmed cases of coronavirus, with 9,783 of them coming from China. In the U.S., only six people have been diagnosed with the illness, while the total global death toll has grown to 213.

Ever since the outbreak first caught mainstream attention, shares of biotech stocks have been even more volatile than normal. Certain vaccine developers, such as Inovio Pharmaceuticals (INO 5.29%), have surged on the possibility of developing a coronavirus vaccine. Inovio announced on Thursday that it came to a research agreement with Beijing Advaccine Biotechnology to speed up the development of a potential treatment.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.99 (5.29%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.